ID: ALA3342961

Max Phase: Preclinical

Molecular Formula: C29H30N2O8

Molecular Weight: 534.57

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(O)CCCN1CC(C(=O)O)Oc2c(NC(=O)c3ccc(OCCCOc4ccccc4)cc3)cccc21

Standard InChI:  InChI=1S/C29H30N2O8/c32-26(33)11-5-16-31-19-25(29(35)36)39-27-23(9-4-10-24(27)31)30-28(34)20-12-14-22(15-13-20)38-18-6-17-37-21-7-2-1-3-8-21/h1-4,7-10,12-15,25H,5-6,11,16-19H2,(H,30,34)(H,32,33)(H,35,36)

Standard InChI Key:  QJLULXIBQDCMAN-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 534.57

Molecular Weight (Monoisotopic): 534.2002

AlogP: 4.30

#Rotatable Bonds: 13

Polar Surface Area: 134.63

Molecular Species: ACID

HBA: 7

HBD: 3

#RO5 Violations: 1

HBA (Lipinski): 10

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 3.20

CX Basic pKa: 0.95

CX LogP: 4.08

CX LogD: -2.46

Aromatic Rings: 3

Heavy Atoms: 39

QED Weighted: 0.27

Np Likeness Score: -0.60

References

1. Itadani S, Takahashi S, Ima M, Sekiguchi T, Fujita M, Nakayama Y, Takeuchi J..  (2014)  Discovery of Highly Potent Dual CysLT1 and CysLT2 Antagonist.,  5  (11): [PMID:25408836] [10.1021/ml500298y]

Source

Source(1):

• Scientific Literature